ARTICLE | Product Development

Better than survival

J&J hopes side effect profile will differentiate abiraterone in prostate cancer

October 18, 2010 7:00 AM UTC

Newly released data from the first Phase III trial of abiraterone acetate from Johnson & Johnson show a survival benefit at least as good as that produced in Phase III trials of Jevtana cabazitaxel, a taxane derivative recently approved in the U.S. to treat metastatic castration-resistant prostate cancer that has progressed following a Taxotere-containing regimen.

J&J plans to submit regulatory applications for abiraterone to treat second-line metastatic CRPC in the U.S. and EU by year end, and hopes the compound's side effect profile will be a differentiating factor versus taxane-based regimens...